Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Classificação em ações #29513
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Preço da ação
$0.12857922
Valor de mercado
$20.96M
Variação (1 dia)
3.63%
Variação (1 ano)
-36.21%
País
FR
Negociar GenSight Biologics S.A. (SIGHT)

Categoria

Histórico de preços das ações de GenSight Biologics S.A. (SIGHT)
Preço de fecho mais alto: $0.11 em 2026-08-01

Preço de fecho mais baixo: $8.93 em 2016-07-01
Histórico de preços das ações da GenSight Biologics S.A. de 2016 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 0.84%
2025 -61.96%
2024 -40.41%
2023 -85.79%
2022 -40.62%
2021 -23.84%
2020 252.34%
2019 -43.91%
2018 -36.71%
2017 -20.44%
2016 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$534.00 36.66%
US
$1.01K 54.27%
NL
$117.42 -19.34%
AU
$752.50 8.47%
CH
$1.07K -5.58%
KR